Bionor releases updated investor presentation
(Oslo, Norway, 21 June 2016) Bionor Pharma ASA (OSE:BIONOR) announced today, that the company has updated its investor presentation.
Reference is made to the stock exchange announcement of 20 June 2016 regarding a contemplated funding process. Attached please find the presentation used for discussions with potential investors. The presentation is also available on the company´s website www.bionorpharma.com.
Unni Hjelmaas, Acting CEO, +47 915 19 651, firstname.lastname@example.org
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 2030 3903, email@example.com
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company’s shareholders. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.